Brokers and banks usually stop taking bids earlier. Check the exact time with yours.
Total Issue Size
Fresh Issue + Offer For Sale
Fresh Issue (FI)
Proceeds go to the company
Offer For Sale (OFS)
Proceeds go to the existing investors
Funding Working Capital Requirements
To meet expanding operational needs and day to day working capital requirements of the company.
Business Development and Digital Marketing
To support geographical expansion, market development, and digital marketing strategies.
General Corporate Purposes
To fulfill general corporate operational needs and fund issue expenses.
(₹ in Crore)
Tap a bar to highlight a metric across periods and show its values.
Himalaya Nutravedics India Limited is a Hyderabad-based pharmaceutical and nutraceutical enterprise established in June 2022. The organization engages in the development, manufacturing, and distribution of classical Ayurvedic medicines alongside modern botanical health supplements. Operating out of an integrated facility located in the Cherlapally industrial zone of Hyderabad, Telangana, the company produces a wide spectrum of dosage options, including oral liquid syrups, solid tablets, hard and soft gelatin capsules, and therapeutic oils. The enterprise utilizes a dual revenue framework combining proprietary brand distribution with contract manufacturing solutions for third-party institutional clients. Under its in-house brand portfolio, the firm formulates and commercializes remedies designed for digestive wellness, joint health, metabolic balance, and immunity support. Its contract manufacturing division offers end-to-end formulation development, automated encapsulation, custom packaging, and supply chain logistics according to precise client specifications. The company's manufacturing facility holds certifications including WHO-cGMP, ISO 9001:2015, and ISO 22000:2018, while maintaining required regulatory approvals from AYUSH and FSSAI. Proceeds from the fresh public offer are directed toward satisfying expanding working capital requirements, augmenting marketing and business development efforts, and addressing general corporate purposes.
The company raised 7.53 crore from anchor investors by allocating 7,10,400 equity shares at an issue price of 106 per share on September 21, 2026.
Source: RHP • Analysis provided for informational purposes
Last Updated: 29 September 2026, 2:00 PM
Comprehensive In-House Manufacturing Capabilities
The company operates an accredited processing center in Hyderabad capable of manufacturing multiple dosage forms under WHO-cGMP and ISO standards.
Diversified Revenue Model Across Brands and B2B Services
Commercial operations generate revenue from both proprietary branded Ayurvedic formulations and specialized third-party contract manufacturing contracts.
Targeted Practitioner Engagement and Outreach Network
A dedicated field team interacts with medical professionals and healthcare practitioners to drive prescription demand across key therapeutic categories.
Geographic Concentration at Single Facility
All manufacturing activity takes place at a single leased location in Cherlapally, Hyderabad, creating operational vulnerabilities to localized disruptions.
Reliance on Key Client Accounts
A significant portion of overall contract manufacturing revenue relies on a concentrated group of corporate customers, exposing revenues to customer loss.
Limited Corporate Operational Track Record
Founded in 2022, the business has a relatively brief operating history in the competitive Indian pharmaceutical and nutraceutical sectors.
Himalaya Nutravedics India Limited
Plot No. 101/A, Phase-III, Industrial Development Park, Cherlapally, Uppal, Hyderabad, Telangana - 500051, India
View on Maps →No financial information whatsoever published anywhere, within this website, should be considered as an advice to buy or sell securities or invest in IPOs, or as a guide to doing so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions.
We are not a SEBI Registered analyst. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on information published on this website. The information on this website is based on information available as on date coupled with market perceptions.
You agree with the terms and conditions to use this website.
Grey-market disclaimer. GMP shown here is grey-market news only. We do not trade or deal in the grey market or subject-to rates, nor do we recommend trading in the grey market.
Not investment advice. IPO Nex is an information tool, not investment advice. We do not recommend buying or selling any securities. Always do your own research before applying to any IPO.
IPO Nex does not guarantee any listing gain or return. IPO investments are subject to market risks.
All times are IST.
© 2026 IPO Nex by Niota. All rights reserved.